Aileron Therapeutics, Inc. (ALRN)

Aileron Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Selling, General & Admin	11.36	9.68	9.6	9.33	12.29
Research & Development	3.99	17.97	17.01	11.17	17.66
Other Operating Expenses	0.93	0	0	0	0
Operating Expenses	16.28	27.65	26.61	20.5	29.96
Operating Income	-16.28	-27.65	-26.61	-20.5	-29.96
Other Expense / Income	-0.54	-0.32	-0.44	0.66	-0.59
Pretax Income	-15.73	-27.33	-26.16	-21.16	-29.37
Net Income	-15.73	-27.33	-26.16	-21.16	-29.37
Shares Outstanding (Basic)	5	5	4	2	1
Shares Outstanding (Diluted)	5	5	4	2	1
Shares Change	1.31%	2.23%	154.70%	42.11%	66.48%
EPS (Basic)	-3.42	-6.02	-5.89	-12.20	-24.00
EPS (Diluted)	-3.42	-6.02	-5.89	-12.20	-24.00
Free Cash Flow	-19.77	-24.87	-23.85	-20.27	-26.63
Free Cash Flow Per Share	-4.30	-5.48	-5.37	-11.63	-21.70
EBITDA	-15.61	-27.16	-26.04	-20.99	-29.21
Depreciation & Amortization	0.12	0.17	0.12	0.16	0.16
EBIT	-15.73	-27.33	-26.16	-21.16	-29.37

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).